A former CAG director general explains how a blockade of one narrow waterway could silently drain the world’s medicine cabinets — with India, supplier of 40% of US generic drugs, most dangerously exposed
By P. SESH KUMAR
New Delhi, March 24, 2026 — A striking claim circulating on social media argues that the world’s medicines are, quite literally, “made of oil” — and that disruptions in the Strait of Hormuz could soon spill over from energy markets into hospital wards and household medicine cabinets.
The Chemistry Behind the Claim: Yes, Our Pills Do Begin in Oil
If we strip away the rhetoric, the first claim holds remarkably well under scrutiny. Modern pharmaceuticals are not grown-they are engineered through industrial chemistry, and that chemistry overwhelmingly begins with hydrocarbons.
Paracetamol, for instance, is produced through the cumene process, where benzene and propylene — both derived from petroleum — are converted into phenol, and then into p-aminophenol before becoming the familiar tablet. (Note: underlying sources confirm petrochemical origin of phenol feedstock)
Ibuprofen follows a similar trajectory, beginning with isobutylbenzene, again a petrochemical derivative. Metformin, the workhorse of global diabetes treatment, is synthesised from dicyandiamide and dimethylamine-both linked to natural gas-based industrial chemistry.
Even beyond active pharmaceutical ingredients (APIs, the ecosystem is saturated with petrochemicals. Solvents like methanol, reagents, coatings, excipients, plastic blister packs, syringes, IV bags, and vaccine vials-all trace back to hydrocarbons. Industry estimates suggest that up to 99% of pharmaceutical feedstocks and reagents are derived from petrochemical sources .
So the first domino is real: modern medicine is chemically inseparable from oil and gas.
The Chokepoint Logic: Why Hormuz Matters More Than Headlines Suggest
The second claim-that this dependence converges dangerously at the Strait of Hormuz-is also grounded in fact, though often simplified.
Roughly one-fifth of global oil flows through this narrow waterway. But more critically for pharmaceuticals, a large share of naphtha-the key feedstock for petrochemical crackers-and industrial chemicals like methanol originates in the Gulf and travels through Hormuz.
Asia’s petrochemical complex-spanning India, China, Japan, and South Korea-relies heavily on these flows. Estimates indicate that over 50% of naphtha imports into Asia come from the Middle East, while India’s exposure for certain chemicals like methanol can exceed 80% through Hormuz-linked routes.
This is where the argument sharpens: a disruption in Hormuz is not just an oil shock. It is a chemical shock, and therefore, potentially, a pharmaceutical shock.
The Shutdown Narrative: Real Signals, Amplified Conclusions
The social media thread highlights multiple “force majeure” declarations and petrochemical plant shutdowns across Asia. These are not fictional.
Reports confirm that companies such as Chandra Asri (Indonesia), Yeochun NCC (South Korea), and Petrochemical Corporation of Singapore have curtailed operations due to feedstock disruptions.
But here is where the narrative needs calibration.
Petrochemical systems are complex, adaptive, and globally networked. A shutdown in one region does not instantly translate into pharmaceutical scarcity. Alternate supply routes, inventory buffers, and substitution mechanisms-though costly-do exist. Markets respond, albeit with friction.
So while the signal (disruption) is real, the leap to imminent systemic collapse is overstated.
India: The True Pressure Point in the Global System
Where the argument becomes genuinely compelling is in its identification of India as the critical node.
India produces approximately 20% of global generic medicines and supplies around 40% of generic drugs consumed in the United States. It is, quite literally, the pharmacy of the developing world.
Yet this pharmaceutical giant rests on a fragile upstream foundation. Its API manufacturing depends heavily on imported intermediates, solvents, and feedstocks tied to petrochemical supply chains.
Policy choices compound this vulnerability. During energy stress, India has historically prioritised household LPG consumption over industrial feedstock allocation. That means petrochemical and chemical industries-upstream of pharma-can face curtailment even before medicines themselves are affected.
Industry estimates suggest Indian pharma companies maintain 3–6 months of inventory buffers. That buys time-but not immunity.
The implication is stark: if disruptions persist beyond a quarter or two, the world’s most important supplier of affordable medicines could itself face constraints.
Vaccines, Plastics, and the Invisible Layer of Dependency
Perhaps the most underappreciated dimension of the argument lies in vaccines and medical infrastructure.
Modern vaccines-especially mRNA-based ones-depend on lipid nanoparticles synthesised through complex chemical pathways rooted in petrochemical intermediates. Traditional vaccines rely on stabilisers, adjuvants, and preservatives that also emerge from chemical processing chains.
Then comes the physical layer: vials, syringes, tubing, cold-chain packaging-all plastic, all petrochemical. The insight here is subtle but powerful. Even if the biological science of vaccines is independent of oil, their delivery system is not.
The Critical Gap: Where the Argument Overreaches
Despite its strengths, the viral narrative contains three important exaggerations.
First, it presents petrochemical dependence as absolute and irreplaceable. While dominant, there are emerging alternatives-bio-based feedstocks, fermentation routes, and green chemistry pathways-that can partially substitute over time.
Second, it assumes linear causality: cracker shutdown equals medicine shortage. In reality, supply chains are buffered, diversified, and responsive, though imperfectly so.
Third, it frames the crisis as immediate. The more accurate framing is lagged vulnerability. The system does not break overnight-but it can fracture over months if stress persists.
The Real Insight: A Fourth Domino That Markets Ignore
Where the argument truly shines is in its systemic framing.
Energy shocks are priced. Fertiliser shocks are tracked. Packaging disruptions are visible. But pharmaceuticals occupy a strange blind spot. They are treated as end-products, not as derivatives of upstream commodity chains.
Yet, as this episode reveals, medicines are simply high-value chemical products embedded in the same supply ecosystem as plastics and fuels. The “fourth domino” is not hypothetical-it is simply underpriced.
Way Forward: Securing the Medicine Supply Chain Before It Becomes a Crisis
The lesson here is not panic-it is preparedness.
First, diversification of feedstocks must become a strategic priority. India and other manufacturing hubs need to reduce dependence on single-route petrochemical imports by expanding domestic refining, alternate sourcing, and chemical recycling pathways.
Second, strategic stockpiling must evolve beyond crude oil. Just as nations maintain petroleum reserves, they must consider reserves of critical APIs, intermediates, and solvents essential for public health.
Third, industrial policy must rebalance priorities. Protecting household fuel access is politically necessary, but starving chemical and pharmaceutical supply chains creates a delayed systemic risk. A calibrated allocation framework is essential.
Fourth, innovation in green chemistry and bio-based synthesis must accelerate. The long-term solution lies not in securing Hormuz, but in reducing dependence on it.
Finally, global coordination is indispensable. The pharmaceutical supply chain is not national-it is planetary. Securing maritime routes, ensuring insurance cover, and maintaining trade flows are as critical for antibiotics as they are for oil.
The viral claim that “the war has reached the medicine cabinet” is not entirely wrong-but it is not entirely right either. What it captures brilliantly is a hidden truth: modern medicine is not insulated from geopolitics. It is deeply entangled in it.
What it exaggerates is immediacy. The real risk is slower, quieter, and far more dangerous-a gradual tightening of supply chains until the world realises, too late, that the most essential product of all had been treated as just another derivative of oil.
IAEA chief warns seizing Iran’s enriched uranium ‘very challenging’
Follow The Raisina Hills on WhatsApp, Instagram, YouTube, Facebook, and LinkedIn
